Therefore, it can be considered a potential target for the CX43-mediated GJCs between GB/astrocytic cells, and so the combination of the CX43 inhibitor with TMZ or VCR could be a successful therapy to GBs (Chen et al., 2015). The gene discussed is GJA1; the disease is Guillain-Barre syndrome.